当前位置：首页 SCI期刊 SCIE期刊医学中科院3区 JCRQ2 期刊介绍(非官网)

Cardiovascular Drugs And TherapySCIE

国际简称：CARDIOVASC DRUG THER 参考译名：心血管药物和治疗

中科院分区
3区
CiteScore分区
Q1
JCR分区
Q2

基本信息：: ISSN：0920-3206; E-ISSN：1573-7241; 是否OA：未开放; 是否预警：否; TOP期刊：否

出版信息：: 出版地区：UNITED STATES; 出版商：Springer US; 出版语言：English; 出版周期：Bimonthly; 出版年份：1987; 研究方向：医学-心血管系统

评价信息：: 影响因子：3.1; H-index：63; CiteScore指数：8.3; SJR指数：0.973; SNIP指数：0.814

发文数据：: Gold OA文章占比：26.52%; 研究类文章占比：73.27%; 年发文量：101; 自引率：0; 开源占比：0.2471; 出版撤稿占比：0; 出版国人文章占比：0.14; OA被引用占比：0.3466...

投稿咨询加急见刊

英文简介期刊介绍 CiteScore数据中科院SCI分区 JCR分区发文数据常见问题

英文简介Cardiovascular Drugs And Therapy期刊介绍

Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field.

Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients.

Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.

期刊简介Cardiovascular Drugs And Therapy期刊介绍

《Cardiovascular Drugs And Therapy》自1987出版以来，是一本医学优秀杂志。致力于发表原创科学研究结果，并为医学各个领域的原创研究提供一个展示平台，以促进医学领域的的进步。该刊鼓励先进的、清晰的阐述，从广泛的视角提供当前感兴趣的研究主题的新见解，或审查多年来某个重要领域的所有重要发展。该期刊特色在于及时报道医学领域的最新进展和新发现新突破等。该刊近一年未被列入预警期刊名单，目前已被权威数据库SCIE收录，得到了广泛的认可。

该期刊投稿重要关注点：

预计审稿时间：约4.5月
医学
PHARMACOLOGY & PHARMACY
SCIE
中科院3区
非预警

Cite Score数据（2024年最新版）Cardiovascular Drugs And Therapy Cite Score数据

CiteScore：8.3
SJR：0.973
SNIP：0.814

学科类别	分区	排名	百分位
大类：Medicine 小类：Pharmacology (medical)	Q1	35 / 272	87%
大类：Medicine 小类：Cardiology and Cardiovascular Medicine	Q1	57 / 387	85%
大类：Medicine 小类：Pharmacology	Q1	65 / 313	79%

CiteScore 是由Elsevier(爱思唯尔)推出的另一种评价期刊影响力的文献计量指标。反映出一家期刊近期发表论文的年篇均引用次数。CiteScore以Scopus数据库中收集的引文为基础，针对的是前四年发表的论文的引文。CiteScore的意义在于，它可以为学术界提供一种新的、更全面、更客观地评价期刊影响力的方法，而不仅仅是通过影响因子(IF)这一单一指标来评价。

历年Cite Score趋势图

中科院SCI分区Cardiovascular Drugs And Therapy 中科院分区

中科院 2023年12月升级版 综述期刊：否 Top期刊：否

大类学科	分区	小类学科	分区
医学	3区	PHARMACOLOGY & PHARMACY 药学 CARDIAC & CARDIOVASCULAR SYSTEMS 心脏和心血管系统	3区 4区

中科院分区表 是以客观数据为基础，运用科学计量学方法对国际、国内学术期刊依据影响力进行等级划分的期刊评价标准。它为我国科研、教育机构的管理人员、科研工作者提供了一份评价国际学术期刊影响力的参考数据，得到了全国各地高校、科研机构的广泛认可。

中科院分区表 将所有期刊按照一定指标划分为1区、2区、3区、4区四个层次，类似于“优、良、及格”等。最开始，这个分区只是为了方便图书管理及图书情报领域的研究和期刊评估。之后中科院分区逐步发展成为了一种评价学术期刊质量的重要工具。

历年中科院分区趋势图

JCR分区Cardiovascular Drugs And Therapy JCR分区

2023-2024 年最新版

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：CARDIAC & CARDIOVASCULAR SYSTEMS	SCIE	Q2	67 / 220	69.8%
学科：PHARMACOLOGY & PHARMACY	SCIE	Q2	126 / 354	64.5%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：CARDIAC & CARDIOVASCULAR SYSTEMS	SCIE	Q2	69 / 220	68.86%
学科：PHARMACOLOGY & PHARMACY	SCIE	Q2	125 / 354	64.83%

JCR分区的优势在于它可以帮助读者对学术文献质量进行评估。不同学科的文章引用量可能存在较大的差异，此时单独依靠影响因子(IF)评价期刊的质量可能是存在一定问题的。因此，JCR将期刊按照学科门类和影响因子分为不同的分区，这样读者可以根据自己的研究领域和需求选择合适的期刊。

历年影响因子趋势图

发文数据

2023-2024 年国家/地区发文量统计

国家/地区数量
USA106
England105
CHINA MAINLAND86
Italy31
GERMANY (FED REP GER)29
Netherlands23
Japan21
Spain20
Greece18
Canada16

本刊中国学者近年发表论文

1、The Function and Therapeutic Potential of Circular RNA in Cardiovascular Diseases
Author: Wang, Kai; Gao, Xiang-Qian; Wang, Tao; Zhou, Lu-Yu

Journal: CARDIOVASCULAR DRUGS AND THERAPY. 2023; Vol. 37, Issue 1, pp. 181-198. DOI: 10.1007/s10557-021-07228-5
2、The Function and Regulation of Platelet P2Y12 Receptor
Author: Li, Xiaohua; Zhang, Guoxing; Cao, Xia

Journal: CARDIOVASCULAR DRUGS AND THERAPY. 2023; Vol. 37, Issue 1, pp. 199-216. DOI: 10.1007/s10557-021-07229-4
3、Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis
Author: Xu, Wenlin; Lv, Meina; Wu, Shuyi; Jiang, Shaojun; Zeng, Zhiwei; Fang, Zongwei; Qian, Jiafen; Chen, Mingrong; Chen, Jiana; Zhang, Jinhua

Journal: CARDIOVASCULAR DRUGS AND THERAPY. 2023; Vol. 37, Issue 2, pp. 363-377. DOI: 10.1007/s10557-021-07232-9
4、Caspofungin Suppresses Brain Cell Necroptosis in Ischemic Stroke Rats via Up-Regulation of Pellino3
Author: Zhang, Yi-Yue; Tian, Jing; Peng, Zi-Mei; Liu, Bin; Peng, Ya-Wei; Zhang, Xiao-Jie; Hu, Zhong-Yang; Luo, Xiu-Ju; Peng, Jun

Journal: CARDIOVASCULAR DRUGS AND THERAPY. 2023; Vol. 37, Issue 1, pp. 9-23. DOI: 10.1007/s10557-021-07231-w
5、Nicorandil Ameliorates Doxorubicin-Induced Cardiotoxicity in Rats, as Evaluated by 7 T Cardiovascular Magnetic Resonance Imaging
Author: Wan, Yixuan; He, Bo; Zhu, Dongyong; Wang, Lei; Huang, Ruijue; Wang, Shiyu; Wang, Chunhua; Zhang, Mengdi; Ma, Lu; Gao, Fabao

Journal: CARDIOVASCULAR DRUGS AND THERAPY. 2023; Vol. 37, Issue 1, pp. 39-51. DOI: 10.1007/s10557-021-07252-5
6、Early Guideline-Directed Medical Therapy and in-Hospital Major Bleeding Risk in ST-Elevation Myocardial Infarction Patients Treated with Percutaneous Coronary Intervention: Findings from the CCC-ACS Project
Author: Li, Ziping; Yang, Pengfei; Geru, A.; Sun, Haonan; Liu, Hangkuan; Song, Xiwen; Jin, Zhengyang; Li, Linjie; Hao, Yongchen; Li, Yongle; Liu, Jing; Zhao, Dong; Zhou, Xin; Yang, Qing

Journal: CARDIOVASCULAR DRUGS AND THERAPY. 2023; Vol. 37, Issue 1, pp. 117-127. DOI: 10.1007/s10557-021-07201-2
7、Differential Expression of LOXL1-AS1 in Coronary Heart Disease and its Regulatory Mechanism in ox-LDL-Induced Human Coronary Artery Endothelial Cell Pyroptosis
Author: Song, Bangrong; Dang, Haiming; Dong, Ran

Journal: CARDIOVASCULAR DRUGS AND THERAPY. 2023; Vol. 37, Issue 1, pp. 75-87. DOI: 10.1007/s10557-021-07274-z
8、Protective Roles of Xijiao Dihuang Tang on Coronary Artery Injury in Kawasaki Disease
Author: Zhang, Jian; Zhuge, Yingzhi; Rong, Xing; Ni, Chao; Niu, Chao; Wen, Zhengwang; Lin, Hongzhou; Chu, Maoping; Jia, Chang

Journal: CARDIOVASCULAR DRUGS AND THERAPY. 2023; Vol. 37, Issue 2, pp. 257-270. DOI: 10.1007/s10557-021-07277-w